Xenon Pharmaceuticals Inc (XENE)

Date: O: H: L: C: Vol:

Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	-	-	-	-	-
	9.64%123.16	112.33	109.77	96.34	94.23
Research and Development	12.11%99.22	88.51	87.70	77.05	74.99
Depreciation and Amortization	4.94%0.56	0.59	0.61	0.64	0.63
Operating Income/Loss	9.64%-123.16	-112.33	-109.77	-96.34	-94.23
Nonoperating Income/Loss	58.74%11.83	7.46	5.04	6.12	8.90
Income/Loss From Continuing Operations Before Tax	6.15%-111.32	-104.87	-104.72	-90.22	-85.33
Income Tax Expense/Benefit, Deferred	534.90%-1.94	0.45	-1.11	-0.70	-0.17
Income Tax Expense/Benefit	77.25%-0.59	-2.57	0.54	0.68	-0.63
	8.24%-110.74	-102.30	-105.26	-90.90	-84.71
Attributable To Parent	8.24%-110.74	-102.30	-105.26	-90.90	-84.71
Basic Average Shares	14.04%99.61	87.35	0.29	79.25	78.95
Diluted Average Shares	14.04%99.61	87.35	0.29	79.25	78.95
Basic Earnings Per Share	5.13%-1.11	-1.17	-1.31	-1.15	-1.07
Diluted Earnings Per Share	5.13%-1.11	-1.17	-1.31	-1.15	-1.07